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Enhanced kinetic stability of [Pd2L4]
4+ cages
through ligand substitution†
Dan Preston,a Samantha M. McNeill,b James E. M. Lewis,a Gregory. I. Gilesb and
James D. Crowley*a
There is considerable interest in exploiting metallosupramolecular cages as drug delivery vectors.
Recently, we developed a [Pd2L4]
4+ cage capable of binding two molecules of cisplatin. Unfortunately,
this ﬁrst generation cage was rapidly decomposed by common biologically relevant nucleophiles. In an
eﬀort to improve the kinetic stability of these cage architectures here we report the synthesis of two
amino substituted tripyridyl 2,6-bis(pyridin-3-ylethynyl)pyridine (tripy) ligands (with amino groups either
in the 2-(2A-tripy) or 3-(3A-tripy) positions of the terminal pyridines) and their respective [Pd2(Ltripy)4]
4+
cages. These systems have been characterised by 1H, 13C and DOSY NMR spectroscopies, high resolution
electrospray mass spectrometry, elemental analysis and, in one case, by X-ray crystallography. It was
established, using model palladium(II) N-heterocyclic carbene (NHC) probe complexes, that the amino
substituted compounds were stronger donor ligands than the parent system (2A-tripy > 3A-tripy > tripy).
Competition experiments with a range of nucleophiles showed that these substitutions lead to more
kinetically robust cage architectures, with [Pd2(2A-tripy)4]
4+ proving the most stable. Biological testing on
the three ligands and cages against A549 and MDA-MB-231 cell lines showed that only [Pd2(2A-tripy)4]
4+
exhibited any appreciable cytotoxicity, with a modest IC50 of 36.4 ± 1.9 µM against the MDA-MB-231 cell
line. Unfortunately, the increase in kinetic stability of the [Pd2(Ltripy)4]
4+ cages was accompanied by loss of
cisplatin-binding ability.
Introduction
Interest in self-assembled coordination complexes of well-
defined two- and three-dimensional geometries, or metallo-
supramolecular architectures,1 continues to grow due to their
potential in a range of applications. The molecular recognition
properties of these systems have been used to develop mole-
cular reactions flasks,2 catalysts3 and drug delivery agents.4
Systems have also been used to sequester reactive species,5
and environmental pollutants.6 Additionally, the biological,7
photophysical,8 electronic9 and redox10 properties of these
metallosupramolecular architectures have been studied.
As part of our interest in the biological properties11 of
metallosupramolecular architectures we have previously
reported the synthesis of a tripyridyl (tripy) [Pd2L4]
4+ cage
capable of binding cisplatin (cis-[Pt(NH3)2Cl2]).
11d We hoped to
exploit these [Pd2L4]
4+ cages as metallosupramolecular drug
delivery vectors, unfortunately the cage architecture was
rapidly decomposed when exposed to chloride (Cl−),11a,d,12 his-
tidine (his)11a and cysteine (cys)11a (common nucleophiles in
biological systems). In order to use these cisplatin binding
[Pd2L4]
4+ cages as drug delivery agents a method for increasing
the kinetic stability of these metallosupramolecular architec-
tures against nucleophiles was required.13 There are two
obvious approaches to enhance the kinetic stability of the cage
architectures: (1) assemble the cage using more kinetically
inert metal ions or (2) sterically and electronically tune the
tripy ligand framework. Exploiting kinetically inert metals for
the generation of metallosupramolecular architectures can be
diﬃcult due to the formation of kinetically “trapped” inter-
mediate structures that cannot “error-correct” into the desired
system. Therefore we chose to generate more electron-donating
tripyridyl ligands in an eﬀort to obtain more kinetically robust
[Pd2L4]
4+ cages. Herein we report the synthesis of two new
amino substituted tripyridyl ligands (2A-tripy and 3A-tripy)
and their respective cages (Scheme 1). The addition of the
amino groups to the 2- and 3-positions of the terminal ligating
pyridyl units of the ligand framework was expected to increase
the donor properties of the ligands and lead to more kineti-
†Electronic supplementary information (ESI) available: The experimental pro-
cedures, 1H, 13C and DOSY NMR, HR-ESMS, crystallographic and computational
data. CCDC 1439952. For ESI and crystallographic data in CIF or other electronic
format see DOI: 10.1039/c6dt00133e
aDepartment of Chemistry, University of Otago, PO Box 56, Dunedin, New Zealand.
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cally robust cage architectures. Additionally, the presence of
the 2-amino units within the [Pd2(2A-tripy)4]
4+ cage architec-
ture was expected to sterically reduce access to the palladium(II)
ions potentially further enhancing the cage lifetime in the
presence of biological nucleophiles. Competition experiments
with Cl−, his and cys nucleophiles showed that the [Pd2(2A-
tripy)4]
4+ cage was more stable than the [Pd2(3A-tripy)4]
4+ cage
which in turn was more stable than the [Pd2(tripy)4]
4+ cage.
Unfortunately, the structural and electronic changes imposed
through amino substitution in the 2-position circumscribe the
ability of the cage to encapsulate cisplatin. Preliminary biologi-
cal testing on these systems indicated that only [Pd2(2A-
tripy)4]
4+ exhibited an IC50 < 50 µM against either of the two
investigated cell lines.
Results and discussion
Synthesis and characterisation
The electronically and sterically tuned tripyridyl ligands (tripy,
2A-tripy, and 3A-tripy, Scheme 1) were synthesised using stan-
dard methods11d,12,14 (ESI†) and characterised using NMR
spectroscopy, high resolution electrospray mass spectrometry
(HR-ESMS), and elemental analysis (Experimental section and
ESI†).
Addition of one of the ligands (tripy, 2A-tripy, and 3A-tripy)
to a solution of [Pd(CH3CN)4](BF4)2 in a 2 : 1 ratio resulted in
the formation of the desired cages (Scheme 1). While the tripy
and 3A-tripy containing cages formed instantaneously at room
temperature, the formation of [Pd2(2A-tripy)4](BF4)4 required
heating in DMSO solution at 50 °C for six hours to complete
the assembly. The cages were characterised using 1H and
DOSY NMR spectroscopy, HR-ESMS, and elemental analysis,
(Experimental and ESI†). The 1H NMR spectra (Fig. 1 and
ESI†) of the [Pd2(Ltripy)4]
4+ cages show a single set of peaks.
The proton resonances due to the terminal pyridyl units of the
cages (Hc–f ) are shifted downfield (Δδ = 0.19–0.59 ppm) relative
to the free tripy ligands, consistent with complexation to palla-
dium(II) ions. Interestingly, the proton resonance of the
2-amino group in the [Pd2(2A-tripy)4](BF4)4 cage displays a very
large (Δδ(HNH) = 1.56 ppm) shift relative to the free ligand
(Fig. 1). Presumably, this large shift is caused by a combi-
nation of coordination to the palladium(II) ions and intra-
ligand hydrogen bonding interactions between the amino
groups on the adjacent ligands. Consistent with this postulate,
the shift of the corresponding proton resonance in the
[Pd2(3A-tripy)4](BF4)4 cage is much smaller (Δδ(HNH) =
0.81 ppm, ESI†). The sharp, uncomplicated signals observed
in the 1H NMR spectra of the [Pd2(Ltripy)4]
4+ systems are
similar to what was previously observed for the formation of
other [Pd2(L)4]
4+ cages and are consistent with the formation
of complexes of high symmetry in solution.11a,d,12
Diﬀusion-ordered 1H NMR spectroscopy (DOSY) provided
additional strong support for the selective formation of the
cages in solution. 1H DOSY spectra (d6-DMSO, 298 K) were
obtained for ligands (tripy, 2A-tripy, and 3A-tripy) and cages
([Pd2(tripy)4]
4+, [Pd2(2A-tripy)4]
4+ and [Pd2(3A-tripy)4]
4+ (ESI†)).
Each of the proton signals in the individual spectra show the
same diﬀusion coeﬃcient (D), indicating that there is only one
species present in solution (ESI†). The Dcomplex/Dligand ratios of
∼0.50 : 1 are similar to those observed for related literature
Scheme 1 Synthesis of the [Pd2(Ltripy)4]
4+ cages from the tripyridyl
ligands (tripy, 2A-tripy, 3A-tripy). Conditions: (i) [Pd(CH3CN)4](BF4)2,
solvent (CH3CN, DMF or DMSO), RT or 50 °C.
Fig. 1 Partial 1H NMR spectra (298 K, 500 MHz, d6-DMSO) of (a) 2A-
tripy and (b) the cage [Pd2(2A-tripy)4](BF4)4.
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compounds11a,d,12 and suggest that the palladium(II) cage
species are stable in solution (ESI†).
Mass spectra (HR-ESMS) of the [Pd2(Ltripy)4]
4+ cage systems
in DMF–CH3CN solution obtained under pseudo cold-spray
conditions displayed overlapping peaks due to [Pd2L4]
4+ and
[PdL2]
2+ ions. Additionally, the spectrum of the 3A-tripy based
cage displayed a peak due to the [Pd2(3A-tripy)4(BF4)2]
2+ ion.
After considerable eﬀort (>50 crystallisations and data col-
lections) the solid state structure of the [Pd2(2A-tripy)4](BF4)4
complex was obtained using X-ray crystallography (Fig. 2 and
ESI†). Small weakly diﬀracting X-ray quality crystals were gen-
erated by vapour diﬀusion of diethyl ether into a CH3CN solu-
tion of the [Pd2(2A-tripy)4](BF4)4 cage. Although the weak
diﬀraction was, at least in part, due to the presence of multiple
disordered solvent molecules and counter anions within the
crystal lattice (vide infra), the cationic framework of the cage
was readily identified (Fig. 2).
The solid state structure of the [Pd2(2A-tripy)4]
4+ cage con-
firms that the coordination of the 2-amino pyridyl units to the
palladium(II) ions was monodentate through the pyridyl nitro-
gen as expected.15 Additionally, the 2-amino units of the
ligands are engaged in intra-ligand hydrogen bonding inter-
actions (N⋯N 3.78(3) Å, N–H⋯N 2.94 Å, Fig. 2b and ESI†) con-
sistent with 1H NMR data described above. In contrast to the
[Pd2(tripy)4]
4+ cage,16 the [Pd2(2A-tripy)4]
4+ cation adopts a
more twisted structure in which the ligands of the 2A-tripy
cages are significantly bent out of planarity and this appears
to be caused by hydrogen bonding interactions between the
amino groups on the exo faces of the architecture. This is
quite diﬀerent to what has been previously observed in the
solid state structures of unsubstituted [Pd2(tripy)4]
4+ cations,
these cages without the 2-amino groups all were found to
adopt a lantern shape, with essentially planar tripy ligands.11a,d,12
The coordinated 2A-tripy ligand distorts in two ways: a swivel-
ling of the coordinating pyridine rings relative to the principal
rotation axis of the molecule (θ = 34.44°–34.64°, compared
with θ = 3.47°–9.42° for [Pd2(tripy)4]
4+) and a twisting of the
central pyridine out of the plane through which the ligand
coordinates to the two Pd(II) centres (φ = 35.10° compared with
φ = 5.61° for [Pd2(tripy)4]
4+). The cavity dimensions also diﬀer
(a Pd⋯Pd distance of 11.530(9)–11.610(9) Å compared with
11.201(1) Å for [Pd2(tripy)4]
4+, and a core-to-core pyridyl N⋯N
distance of 10.711(9)–10.732(9) Å compared with 11.07(1)–
11.26(1) Å for [Pd2(tripy)4]
4+, Table 1).
Interestingly, the central cavity of the [Pd2(2A-tripy)4]
4+ cage
is filled in the solid state. The exo-methylene alcohol (CH2OH)
substituents from the four neighbouring cages in the crystal
lattice penetrate into the cavity of each cage and form a hydro-
gen bonding interaction (O⋯N 2.74(3) Å, O–H⋯N 1.91 Å,
Fig. 3 and ESI†) with the endo-pyridyl unit. These interactions
generate 2D supramolecular sheets of cages through the solid
state structure (Fig. 3 and ESI†).
Competition experiments, cisplatin binding and cytotoxicity
studies
The relative pKa values of 2-aminopyridine (6.82), 3-aminopyri-
dine (6.04), and pyridine (5.23) indicate that 2-aminopyridine
is the most basic ligand.17 Evidence that 2-aminopyridine was
also the strongest nucleophile was obtained using the palla-
dium(II)-N-heterocyclic carbene (NHC) probe system developed
by Huynh and coworkers (Table 2 and ESI†).18 Consistent with
the pKa values, the probe complexes indicated that 2-amino-
pyridine (161.2 ppm) is a stronger donor than 3-aminopyri-
dine (159.8 ppm) which is a stronger donor than pyridine
(159.3 ppm). The chemical shift observed for the 2-aminopyri-
dine ligand is very similar to that previously reported for
N-methylimidazole (161.1 ppm)18b suggesting that the donor
strength of these ligands are similar. To allow direct compari-
son to the literature pKa values (Table 2) and for synthetic con-
venience11a we have examined the probe complexes of the
simpler pyridine rather than the tripyridyl ligands. However,
these pyridine model systems can serve as proxies for their
respective tripyridyl ligands (2A-tripy, 3A-tripy, tripy) and
provide indirect experimental evidence for the donor pro-
perties of the tripy ligands because the steric and electronic
changes on going from the pyridine to tripy ligands are the
Fig. 2 Molecular structure of [Pd2(2A-tripy)4]
4+ cations determined
using X-ray crystallography: (a) a ball-and-stick representation of
[Pd2(2A-tripy)4]
4+ cation; (b) a partial view of the [Pd2(2A-tripy)4]
4+
cation from the top showing the hydrogen bonding interactions
between the 2-amino substituents of the ligands. Solvent molecules and
counterions omitted for clarity. Colours: magenta = palladium, grey =
carbon, white = hydrogen, blue = nitrogen, red = oxygen.
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same across the series. Thus the model complexes provide a
qualitative ranking of the substituents’ eﬀects present in the
tripy ligands and strongly suggest that the donor properties of
the tripyridyl ligands follow the order 2A-tripy > 3A-tripy >
tripy.
The kinetic stability of the [Pd2(Ltripy)4]
4+ architectures in
the presence of common biological nucleophiles (Cl−, his and
cys) was determined using 1H NMR competition experiments
(Table 2 and ESI†). Time-course 1H NMR competition experi-
ments were carried out in 3 : 2 d6-DMSO/D2O where 3 mM
solutions of each cage were treated with 8 equivalents of tetra-
methylammonium chloride or 4 equivalents of his or cys.
Under these conditions the unsubstituted [Pd2(tripy)4]
4+ cage
was rapidly decomposed by all the nucleophiles. The half-life
for the decomposition of the [Pd2(tripy)4]
4+ complex with his
was 18 minutes. Despite the [Pd2(3A-tripy)4]
4+ architecture con-
taining the slightly more electron rich 3A-tripy ligand the cage
was still quickly decomposed by each of the nucleophiles.
However, the t1/2 were subtly increased against all the nucleo-
philes (for his t1/2 = 25 min) suggesting that the enhanced
ligand donor properties of the 3A-tripy ligand does lead to
increased cage stability relative to the unsubstituted system.
The [Pd2(2A-tripy)4]
4+ cage displayed markedly higher stabi-
lity against all the nucleophiles studied. The half-lives for the
2A-tripy cage decomposition against each nucleophile were all
over 2 h, whereas the corresponding t1/2 for the other cages
were all less than 30 min. 2A-tripy is only a modestly stronger
donor ligand than the 3A-tripy, and thus the observed large
diﬀerence in stability is presumably not predominantly due to
the increase donor ability of the ligand. A more important
element is likely to be the presence of the 2-amino groups on
the exo-faces of the [Pd2(2A-tripy)4]
4+ cage which sterically
protect the palladium(II) ions from the incoming nucleophiles.
Additionally, as observed in the X-ray structure (Fig. 3), the
hydrogen bonding interactions between the eight amino
groups of the four 2A-tripy ligands may further enhance the
stability of the [Pd2(2A-tripy)4]
4+ cage relative to the other tripy
architectures. However, against the stronger nucleophiles (Cl−
and cys) the half-lives for the decomposition of the [Pd2(2A-
tripy)4]
4+ are less than 3 h suggesting that these systems would
need further tuning in order to be useful in a biological
setting.
Cisplatin binding
We11d,12,19 and others16 have previously shown that other
similar [Pd2(tripy)4]
4+ cages can encapsulate cisplatin through
hydrogen bonding interactions in CH3CN and DMF solvents.
20
Fig. 3 The crystal packing of [Pd2(2A-tripy)4]
4+ cations showing (a) the
interdigitation of the methylene alcohol substituents on adjacent
[Pd2(2A-tripy)4]
4+ cations into the central cavity of the [Pd2(2A-tripy)4]
4+
cation (cage shown in ball-and-stick, methylene alcohol substituents in
spaceﬁlling view), and (b) the extended lattice.
Table 1 Selected crystallographic distances and angles from [Pd2(2A-
tripy)4]
4+ and [Pd2(tripy)4]
4+ 16
[Pd2(2A-tripy)4]
4+ [Pd2(tripy)4]
4+ 16
Θ (°)a 34.44°–34.64° 3.47°–9.42°
Φ (°)b 35.10° 5.61°
d(Pd(II)⋯Pd(II)) (Å) 11.53(9)–11.610(9) Å 11.201(1) Å
d(Ncore⋯Ncore) (Å) 10.71(9)–10.73(9) Å 11.07(1)–11.26(1) Å
a θ: the swivelling of the coordinating pyridine rings relative to the
principal rotation axis of the molecule. b φ: twisting of the central
pyridine out of the plane through which the ligand coordinates to the
two Pd(II) centres.
Table 2 pKa values,
13C NMR chemical shifts of NHC carbene of the
model probe complexes, and half-lives (t1/2) for the decomposition of
the [Pd2(Ltripy)4]
4+ architectures against selected biologically relevant
nucleophiles (3 : 2 d6-DMSO/D2O, 298 K, 500 MHz) as measured
through time-course 1H NMR spectroscopy
Compound pKa
13C δa
(ppm)
Cl−
(8 eq.)
his
(4 eq.)
cys
(4 eq.)
[Pd2(tripy)4](BF4)4 5.23
17 159.3a,18 >1 min 18 min 6 min
[Pd2(2A-tripy)4](BF4)4 6.82
17 161.2a 2 h 46 h 3 h
[Pd2(3A-tripy)4](BF4)4 6.04
17 159.8a 10 min 25 min 10 min
a Chemical shift (ppm) of the NHC carbene carbon in the model Pd(II)
probe complexes (ESI).
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1H NMR spectroscopy and recently reported crystallographic
evidence16b confirms that despite the presence of the potential
hydrogen bond donor CH2OH units of the exo surface of the
[Pd2(tripy)4]
4+ cage the system retains the ability to bind cis-
platin. Addition of an excess of cisplatin to a d7-DMF solution
of [Pd2(tripy)4]
4+ resulted in a large downfield shift (Δδ =
0.24 ppm) of the internally directed cage proton Hc (Fig. 4a
and b) indicative of cisplatin binding within the cage cavity.
The solid state structure16b of the [(cisplatin)2⊂Pd2(tripy)4]4+
host–guest adduct has recently been reported by Casini, Kuhn
and co-workers and is very similar to what we have previously
observed in related systems.11d,19b Consistent with the 1H NMR
evidence, the [Pd2(tripy)4]
4+ cation binds two molecules of cis-
platin within the cavity of the cage.16 The guest molecules are
rotated 180° with respect to each other; hydrogen bonds
between the guests and cage (N–H⋯NPy and Cl⋯H–CPy) as
well as a metal–metal interaction between the platinum atoms
of the guests were observed (Fig. 3a).11d,16b,19b
A similar 1H NMR experiment with cisplatin and [Pd2(3A-
tripy)4]
4+ indicated that the 3-amino substituted cage is also
able to bind cisplatin in solution, albeit more weakly (Δδ =
0.07 ppm for Hc, Fig. 4c and d) than the parent [Pd2(tripy)4]
4+
cage. Conversely, 1H NMR spectra of the [Pd2(2A-tripy)4]
4+ cage
in the presence of cisplatin acquired in either deuterated
CH3CN or DMF solvents displayed no shifts relative to the free
cage indicating that the 2-amino substituted cage is not able
to bind cisplatin. We have previously shown that cisplatin
binding is very weak12 and that subtle changes to the size,
steric profile and electronic properties of the cage cavity21 are
enough to completely turn oﬀ cisplatin binding. Presumably,
the lack of cisplatin binding in this system can be ascribed to
two factors. Firstly, the presence of the eight amino groups on
the exo faces of the cage has caused a twisting of the architec-
ture (as indicated in the crystal structure, Fig. 3, and discussed
and listed in Table 1). This twisting subtly alters both the size
of the cisplatin binding cavity and the orientations of the
hydrogen-bond acceptors and donors groups within the cage
cavity, weakening the interaction between the host and the cis-
platin guest. Secondly, the electron donating 2-amino units
push electron density back onto the terminal pyridyl rings of
the tripy ligand. This would reduce the polarisation of the
acidic Hc protons of the pyridyl unit, weakening the hydrogen
bonding interaction with chloride ligands of the cisplatin
guest. These eﬀects, in concert, appear to be enough to fully
circumscribe the already weak cisplatin–cage interaction.22
Cytotoxicity
While the improvement of kinetic stability of the [Pd2(2A-
tripy)4]
4+ cage has been achieved at the expense of host–guest
capacity, recent work has shown that [Pd2(L)4]
4+ architectures
can act as biological agents in their own right.11a,23 Accord-
ingly, a preliminary investigation of the cytotoxic properties
of the three cages (and the corresponding ligands) was under-
taken against two cell lines: A549 (lung cancer) and cisplatin-
resistant MDA-MB-231 (breast cancer) (Table 3). We have
previously determined the IC50 values for cisplatin against
these two cell lines, which were 9.4 ± 0.3 µM (A549)24 and
41.2 ± 3.9 µM) (MDA-MB-231)11b respectively. None of the
ligands exhibited significant cytotoxicity (IC50 > 200 µM)
against these cell-lines. Similarly, neither of the unstabilised
cages, [Pd2(tripy)4](BF4)4 or [Pd2(3A-tripy)4](BF4)4 (IC50 >
50 µM) nor the palladium(II) tetrafluoroborate salt (IC50 >
100 µM))11a [Pd(CH3CN)4](BF4)4 displayed any appreciable cyto-
toxic eﬀect. The most kinetically stable cage [Pd2(2A-tripy)4]
(BF4)4 displayed low cytotoxicity against the A549 cell line
(IC50 > 50 µM), and slightly higher cytotoxicity against the
Fig. 4 Partial 1H NMR spectra (298 K, 500 MHz, d7-DMF) of (a)
[Pd2(tripy)4](BF4)4, (b) [(cisplatin)2⊂Pd2(tripy)4](BF4)4 and (c) [Pd2(3A-
tripy)4](BF4)4 and (d) [(cisplatin)2⊂Pd2(3A-tripy)4](BF4)4.
Table 3 IC50 values for [Pd2(Ltripy)4]
4+ and related literature [Pd2(L)4]
4+ compounds against selected cell lines
Compound
IC50 (µM)
A549 (lung) MDA-MB231 (breast) HL-60 (leukemia) SKW-3 (leukemia)
Ligand Cage Ligand Cage Ligand Cage Ligand Cage
[Pd2(tripy)4](BF4)4 >200 >50 >200 >50 — — — —
[Pd2(2A-tripy)4](BF4)4 >200 >50 >200 36.4 ± 1.9 — — — —
[Pd2(3A-tripy)4](BF4)4 >200 >50 >200 >50 — — — —
[Pd2(La)4](BF4)4 (La = hextrz)
11a 28.5 ± 2.6 6.9 ± 0.9 89.8 ± 10.7 6.0 ± 0.6 — — — —
[Pd2(Lb)4](BF4)4 (Lb = dipy-dianthracenyl)
23 — — — — >100 1.9 ± 0.2 >80 1.8 ± 0.2
Cisplatin — 9.4 ± 0.3 — 41.2 ± 3.9 — 8.1 ± 1.4 — 9.3 ± 2.1
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MDA-MB-231 cell line (IC50 = 36.4 ± 1.9 µM). We have pre-
viously shown that a more kinetically robust and hydrophobic
[Pd2(La)4]
4+ helicate (La = 1,3-bis(1-hexyl-1H-1,2,3-triazol-4-yl)
benzene) was considerably more cytotoxic (IC50 = 6.9 ± 0.9 and
6.0 ± 0.6 µM) against both the A549 and MDA-MB-231 cell
lines.11a Additionally, Yoshizawa and co-workers have recently
reported that a hydrophobic [Pd2(Lb)4]
4+ cage (Lb = 3,3′-((4,5,6-
tris(2-methoxyethoxy)-1,3-phenylene)bis(anthracene-10,9-diyl))-
dipyridine) is highly cytotoxic (IC50 = 1.8 and 1.9 µM) against
HL-60 and SKW-3 cancer cell lines.23 Thus it is presumed that
low cytotoxicity of the systems described here is connected to the
combination of both high kinetic lability and the more hydro-
philic nature of the [Pd2(Ltripy)4]
4+architectures and ligands.
Conclusions
Two amino substituted tripyridyl 2,6-bis(pyridin-3-ylethynyl)
pyridine (tripy) ligands (with amino groups either in the 2-(2A-
tripy) or 3-(3A-tripy) positions of the terminal pyridines) and
their respective [Pd2(Ltripy)4]
4+ cages were synthesised. These
systems have been characterised by 1H, 13C and DOSY NMR
spectroscopies, high resolution electrospray mass spectro-
metry, elemental analysis and, in one case, by X-ray crystallo-
graphy. It was established, using palladium(II) NHC carbene
probe model complexes, that the amino substituted com-
pounds were moderately stronger donor ligands than the
parent pyridyl system (2A-tripy > 3A-tripy > tripy). Competition
experiments with common biological nucleophiles (Cl−, his
and cys) showed that the [Pd2(2A-tripy)4]
4+ cage proved the
most kinetically stable, presumably due to a favourable combi-
nation of enhanced ligand donor strength, and probably more
importantly, intramolecular hydrogen bonding and steric
shielding. Preliminary biological investigations against two
cell lines (A549 and MDA-MB-231) found that all ligands and
cages had IC50 values >50 µM, with the exception of [Pd2(2A-
tripy)4]
4+ which against MDA-MB-231 has an IC50 of 36.4 ±
1.9 µM.
However, while the ligand tuning resulted in more robust
[Pd2(Ltripy)4]
4+ architectures the half-lives of the systems
against the stronger nucleophiles were still modest (t1/2 =
2–3 h). Furthermore, the subtle structural changes in the most
stabilised cage, [Pd2(2A-tripy)4]
4+ were found to completely
destroy the ability of the system to bind cisplatin. Thus, it
appears that in order to exploit these types of metallosupra-
molecular cage architectures as drug delivery vectors, systems
assembled from more kinetically inert metals ions such as
Pt(II)4h and Ru(II)4e–g and Co(III)25 will be required. Eﬀorts to
generate more robust systems, composed of kinetically inert
metal ions, capable of binding drug molecules are underway.
Experimental
General
Unless otherwise stated, all reagents were purchased from
commercial sources and used without further purification. 2,5-
Dibromo-4-(hydroxymethyl)pyridine,26 5-iodo-2-aminopyridi-
ne,6a the dimeric dibromobis(benzimidazolin-2-ylidene)di-
palladium(II) complex,27 and trans-dibromo(1,3-diisopropyl-
benzimidazolin-2-ylidene)(pyridine)palladium(II)18b were syn-
thesised according to literature procedures. Solvents were labo-
ratory reagent grade. Petroleum ether refers to the fraction of
petrol boiling in the range 40–60 °C, isopropyl alcohol (IPA),
methanol (CH3OH), dichloromethane (CH2Cl2), ethylenediamine-
tetraacetate (EDTA), ethynyltrimethylsilane (TMS-acetylene),
tetrahydrofuran (THF), dimethyl sulfoxide (DMSO), dimethyl-
formamide (DMF). 1H and 13C NMR spectra were recorded on
either a 400 MHz Varian 400-MR or Varian 500 MHz AR
spectrometer. Chemical shifts are reported in parts per
million and referenced to residual solvent peaks (CDCl3:
1H δ 7.26 ppm, 13C δ 77.16 ppm; CD3CN:
1H δ 1.94, 13C δ 1.32,
118.26 ppm, d6-DMSO:
1H δ 2.50 ppm; 13C δ 39.52 ppm). Coup-
ling constants ( J) are reported in Hertz (Hz). Standard abbrevi-
ations indicating multiplicity were used as follows: m =
multiplet, q = quartet, t = triplet, dt = double triplet, d =
doublet, dd = double doublet, s = singlet, br = broad. Full
1H and 13C NMR spectra, together with structural labelling are
included in the ESI.† IR spectra were recorded on a Bruker
ALPHA FT-IR spectrometer with an attached ALPHA-P
measurement module. Microanalyses were performed at the
Campbell Microanalytical Laboratory at the University of
Otago. Electrospray mass spectra (ESMS) were collected on a
Bruker microTOF-Q spectrometer.
Synthesis of 5-iodopyridin-2-acetamide (1). A solution of
5-iodopyridin-2-amine (2.5 g, 11.4 mmol) in triethylamine
(10 mL) and CH2Cl2 (50 mL) was degassed with N2 for
15 minutes. Acetic anhydride (10.7 mL, 110 mmol) was added
and the mixture was stirred at room temperature for 18 hours.
After removal of solvents under vacuum, the crude mixture
was dissolved in 3 : 1 CHCl3/IPA (150 mL), and washed with
saturated aqueous NaHCO3 solution (2 × 75 mL), and brine
(75 mL). The organic layer was dried over MgSO4, filtered and
the solvent removed under vacuum. Column chromatography
on silica (1 : 19 acetone/CH2Cl2) gave the product as a brown
solid (2.3 g, 8.8 mmol, 77%). 1H NMR (400 MHz, d6-DMSO,
298 K) δ: 10.58 (1H, s, HNH), 8.50 (1H, d, J = 2.3 Hz, Ha), 8.07
(1H, d, J = 8.8 Hz, Hb), 7.94 (1H, d, J = 8.8 Hz, Hc), 2.08 (3H, s,
Hd).
13C NMR (100 MHz, d6-DMSO, 298 K) δ: 169.4, 153.3 (Ca),
151.2, 145.8 (Cb), 115.3 (Cc), 85.7, 23.9 (Cd). HR ESI-MS
(CHCl3) m/z = 284.95 [M + Na]
+ (calc. For C7H7IN2NaO, 284.95).
IR: ν (cm-1) 3215, 3139, 3079, 3018, 1676, 1660, 1520, 1362,
1298, 829, 799. Anal. calcd for: C7H7IN2O: C, 32.08; H, 2.69;
N, 10.69%. Found: C, 32.30; H, 2.55; N, 10.71%.
Synthesis of N-(5-((trimethylsilyl)ethynyl)pyridin-2-yl)aceta-
mide (2). A round bottom flask containing 1 (1.00 g,
3.82 mmol), CuI (0.07 g, 0.38 mmol) and Pd(PPh3)2Cl2 (0.19 g,
0.27 mmol) was purged with N2. Triethylamine (20 mL) was
added via syringe and the solution was degassed with N2 for
15 minutes. After adding TMS-acetylene (0.68 g, 0.93 mL,
6.87 mmol) via syringe, the reaction was heated at reflux under
N2 for 48 hours. The solvent was removed under vacuum, and
the resulting solid was taken up in 3 : 1 CHCl3/IPA (40 mL).
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The solution was stirred with aqueous 0.1 M EDTA/NH4OH
solution (40 mL) for 1.5 hours. After washing with
aqueous 0.1 M EDTA/NH4OH (50 mL) and brine (100 mL), the
organic layer was dried with Na2SO4, filtered, and the solvent
removed under vacuum. The solid was purified through
column chromatography on silica (1 : 19 acetone/CH2Cl2),
giving the product as a brown solid (0.86 g, 3.72 mmol, 97%).
1H NMR (500 MHz, CDCl3, 298 K) δ: 8.34 (1H, d, J = 1.6 Hz,
Hd), 8.17 (1H, d, J = 8.7 Hz, Hb), 8.07 (1H, br, HNH), 7.77 (1H,
dd, J = 8.7 Hz, 2.1 Hz, Hc), 2.21 (3H, s, Ha), 0.25 (15H, s, He).
13C NMR (125 MHz, CDCl3, 298 K) δ: 168.5, 150.9 (Cd), 150.3,
141.4 (Cc), 116.0, 112.9 (Cb), 101.4, 97.1, 24.8 (Ca), −0.1 (Ce).
HR ESI-MS (CHCl3) m/z = 255.09 [M + Na]
+ (calc. for
C12H16N2NaOSi, 255.09). IR: ν (cm
−1) 3243, 2955, 2161, 1697,
1579, 1526, 1380, 1303, 1246, 1030. Anal. calcd for
C12H16N2OSi·0.5 acetone: C, 62.03; H, 7.14; N, 11.35%. Found:
C, 61.94; H, 7.29; N, 11.35%.
Synthesis of 5-ethynylpyridin-2-amine (3). A solution of 2
(0.63 g, 2.70 mmol) and NaOH (1.08 g, 27.0 mmol) in metha-
nol (30 mL) was heated at reflux for 1.5 hours before removal
of solvent under vacuum, with the resultant residue taken up
in 3 : 1 CHCl3/IPA (100 mL) and washed with water (100 mL)
and brine (100 mL). After drying with Na2SO4 and filtration,
the solvent was removed under vacuum, and purification
through column chromatography on silica (1 : 8 acetone/
CH2Cl2) gave the product as a brown solid (0.22 g, 1.90 mmol,
70%). 1H NMR (500 MHz, CDCl3, 298 K) δ: 8.22 (1H, dd, J =
2.2 Hz, 0.8 Hz, Hc), 7.53 (1H, dd, J = 8.6 Hz, 2.3 Hz, Hb), 6.46
(1H, dd, J = 8.6 Hz, 0.8 Hz, Ha), 4.69 (2H, br, HNH), 3.06 (s, Hd).
13C NMR (125 MHz, CDCl3, 298 K) δ: 157.6, 151.6 (Cc), 141.0
(Cb), 108.7, 108.0 (Ca), 81.2, 77.8 (Cd). IR: ν (cm
−1) 3326, 3295,
3163, 2148, 1645, 1585, 1424, 1329, 1246, 1156. Anal. calcd for
C7H6N2·0.1 acetone: C, 70.74; H, 5.37; N, 22.60%. Found:
C, 70.44; H, 5.17; N, 22.56%.
Synthesis of N-(5-((trimethylsilyl)ethynyl)pyridin-3-yl)acet-
amide (4). A glass tube containing diisopropylamine (7 mL)
degassed with N2 was charged with 5-bromopyridin-3-amine
(500 mg, 2.89 mmol), CuI (55 mg, 0.29 mmol), Pd(dppf)2Cl2
(85 mg, 0.17 mmol) and TMS-acetylene (1.173 mL, 852 mg,
8.67 mmol) against a positive N2 flow. The tube was sealed
and stirred at 60 °C for 72 hours. 3 : 1 CHCl3/IPA (100 mL) and
aqueous 0.1 M EDTA/NH4OH solution (100 mL) were added
and the mixture stirred for one hour. The organic layer was
washed with water (50 mL) and brine (50 mL), dried over
Na2SO4, filtered, and the solvent was removed under vacuum.
The resultant solid was purified by column chromatography
(1 : 8 acetone/CH2Cl2) to give the product as a brown solid
(512 mg, 2.71 mmol, 94%). 1H NMR (500 MHz, CDCl3, 298 K)
δ: 8.10 (1H, d, J = 1.5 Hz, Hc), 8.01 (1H, d, J = 2.7 Hz, Ha), 7.04
(1H, dd, J = 2.7 Hz, 1.7 Hz, Hb), 0.25 (9H, s, Hd).
13C NMR
(125 MHz, CDCl3, 298 K) δ: 142.9 (Cc), 141.9, 136.8 (Ca), 124.1
(Cb), 120.3, 101.9, 97.6, 0.0 (Cd). HR ESI-MS (MeOH) m/z =
191.10 [M + H]+ (calc. for C10H15N2Si, 191.10). Anal. calcd for
C10H14N2OSi: C, 63.11; H, 7.41; N, 14.62%; found: C, 63.40;
H, 7.48; N, 14.62%. IR: ν (cm−1) 3327, 3295, 3162, 2147, 1585,
1424, 1329, 1245.
Synthesis of 5-ethynylpyridin-3-amine (5). A solution of 4
(0.43 g, 2.3 mmol) in methanol (30 mL) with Na2CO3 (0.48 g,
4.5 mmol) was stirred at room temperature for 1 h. After fil-
tration, the solvent was removed under vacuum, and the resul-
tant solid was purified by column chromatography on silica
(1 : 8 acetone/CH2Cl2) to give the product as a brown solid
(0.25 g, 2.1 mmol, 96%). 1H NMR (500 MHz, CDCl3, 298 K)
δ: 8.13 (1H, d, J = 2.7 Hz, Hc), 8.05 (1H, d, J = 2.7 Hz, Ha), 7.06
(1H, dd, J = 2.7 Hz, 2.7 Hz, Hb), 3.71 (2H, br, HNH), 3.14 (1H, s,
Hd).
13C NMR (125 MHz, CDCl3, 298 K) δ: 143.0 (Cc), 141.8,
137.1 (Ca), 124.0 (Cb), 119.1, 80.7, 79.8 (Cd). IR: ν (cm
−1) 3328,
3295, 3163, 3020, 2148, 1644, 1585, 1424, 1329, 1246. Anal.
calcd for C7H6N2·0.1 (acetone): C, 70.74; H, 5.37; N, 22.60%.
Found: C, 70.96; H, 5.14; N, 22.80%. Mass spectral analysis
was not successful for this compound.
Synthesis of tripy. A round bottom flask containing (2,6-
dibromopyridin-4-yl)methanol (336 mg, 1.26 mmol), 3-ethynyl-
pyridine (325 mg, 3.15 mmol), CuI (24 mg, 0.12 mmol) and Pd
(PPh3)2Cl2 (35 mg, 0.05 mmol) was purged with N2, before
addition of triethylamine (25 mL) and dry THF (25 mL). The
reaction was stirred in the absence of light for 24 hours.
CH2Cl2 (50 mL) and aqueous 0.1 M EDTA/NH4OH solution
(100 mL) were added and the mixture stirred at room tempera-
ture for 2 hours. After extraction into CH2Cl2 (2 × 100 mL), the
combined organic layers were washed with brine (100 mL),
dried over MgSO4, and then filtered. The solvent was removed
under vacuum. Column chromatography (2 : 3 CH2Cl2/acetone)
gave the product as a colourless solid (280 mg, 0.90 mmol,
71%). 1H NMR (500 MHz, CD3CN, 298 K) δ: 8.81 (2H, dd, J =
2.1 Hz, 0.8 Hz, Hc), 8.61 (2H, dd, J = 4.9 Hz, 1.7 Hz, Hf), 7.98
(2H, ddd, J = 7.9 Hz, 2.2 Hz, 1.7 Hz, Hd), 7.58 (2H, t, J = 0.9 Hz,
Hb), 7.41 (2H, ddd, J = 7.9 Hz, 4.9 Hz, 0.9 Hz, He), 4.67 (2H, dt,
J = 5.9 Hz, 0.8 Hz, Ha), 3.55 (1H, t, J = 5.9 Hz, HOH).
13C NMR
(500 MHz, CD3CN, 298 K) δ: 154.1, 153.3 (Cc), 150.6 (Cf), 143.8,
139.9 (Cd), 125.3 (Cb), 124.4 (Ce), 119.9, 91.8, 86.2, 62.4 (Ca).
HR ESI-MS (acetone) m/z = 645.21 [2M + Na]+ (calc. for
C40H26N6NaO2, 645.20), 334.10 [M + Na]
+ (calc. for
C20H13N3NaO, 334.10). IR: ν (cm
−1) 3204, 3032, 2923, 2213,
1685, 1596, 1547, 1475, 1415, 1189, 1076, 1023. Anal. calcd for
C20H13N3O·0.25 acetone: C, 76.48; H, 4.49; N, 12.90%. Found:
C, 76.70; H, 4.49; N, 13.06%.
Synthesis of 2A-tripy. In a round bottom flask, diisopropyl-
amine (20 mL) and THF (20 mL) were degassed with N2, before
addition of 3 (400 mg, 3.39 mmol), (2,6-dibromopyridin-4-yl)
methanol (362 mg, 1.35 mmol), CuI (25 mg, 0.14 mmol), and
Pd(PPh3)2Cl2 (38 mg, 0.050 mmol) against a positive N2 flow.
The solution was heated at 50 °C for 48 hours. After removal of
the solvent under vacuum, the resultant solid was taken up in
3 : 1 CHCl3/IPA (150 mL) and aqueous 0.1 M EDTA/NH4OH
solution (50 mL) and stirred for 40 minutes. The organic layer
was washed with brine, dried with Na2SO4, filtered and then
the solvent was removed under vacuum. Purification of the
resultant solid on a silica column deactivated with 3 : 97 tri-
ethylamine/CH2Cl2 (0.5/4.5/95 then 1/9/90 saturated aqueous
NH4OH solution/MeOH/CH2Cl2) gave the product as a brown
solid (364 mg, 1.07 mmol, 79%). 1H NMR (500 MHz, d6-DMSO,
Paper Dalton Transactions
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298 K) δ: 8.18 (2H, dd J = 2.3 Hz, 0.5 Hz, Hc), 7.57 (2H, dd, J =
8.6 Hz, 2.3 Hz, Hd), 7.42 (2H, s, Hb), 6.55 (4H, s, HNH), 6.49
(2H, dd, J = 8.6 Hz, 0.6 Hz, He), 5.51 (1H, t, J = 5.8 Hz, HOH),
4.54 (2H, d, J = 5.7 Hz, Ha).
13C NMR (500 MHz, d6-DMSO,
298 K) δ: 159.7, 153.0, 152.0 (Cc), 142.9, 139.7 (Cd), 122.6 (Cb),
107.7 (Ce), 104.9, 88.8, 88.0, 60.9 (Ca). HR ESI-MS (CH3CN) m/z
= 683.26 [2M + H]+ (calc. for C40H31N10O2, 683.26), 342.13
[M + H]+ (calc. for C20H16N5O, 342.14). IR: ν (cm
−1) 3307, 3145,
2920, 2201, 1670, 1634, 1593, 1543, 1505, 1393, 1171, 1140,
1055, 1016. Anal. calcd for C20H15N5O·CH2Cl2: C, 69.00;
H, 4.38; N, 20.02%. Found: C, 69.12; H, 4.51; N, 20.33%.
Synthesis of 3A-tripy. In a round bottom flask, diisopropyl-
amine (20 mL) and THF (20 mL) were degassed with N2, before
5 (365 mg, 3.09 mmol), (2,6-dibromopyridin-4-yl)methanol
(275 mg, 1.03 mmol), CuI (20 mg, 0.10 mmol), and Pd
(PPh3)2Cl2 (36 mg, 0.05 mmol) were added against a positive
N2 flow. The solution was heated at 40 °C for 48 hours. After
removal of the solvent under vacuum, the resultant solid was
taken in 3 : 1 CHCl3/IPA (150 mL) and aqueous 01. M EDTA/
NH4OH solution (50 mL) and stirred for 40 minutes. The
organic layer was washed with brine (100 mL), dried with
Na2SO4, filtered, and then the solvent was removed under
vacuum. Purification of the resultant solid in a silica column
deactivated with 3 : 97 triethylamine/CH2Cl2 (0.5/4.5/95 then
1/9/90 saturated aqueous NH4OH solution/MeOH/CH2Cl2) gave
the product as a brown solid (197 mg, 0.58 mmol, 56%).
1H NMR (500 MHz, d6-DMSO, 298 K) δ: 7.99 (2H, d, J = 2.9 Hz,
He), 7.96 (2H, d, J = 1.6 Hz, Hc), 7.59 (2H, s, Hb), 7.09 (2H, t, J =
2.2 Hz, Hd), 5.60 (5H, m, HNH & HOH), 4.59 (2H, d, J = 5.8 Hz,
Ha).
13C NMR (125 MHz, d6-DMSO, 298 K) δ: 153.6, 144.5,
142.2, 139.2 (Cc), 136.9 (Ce), 124.2 (Cb), 121.3 (Cd), 117.8, 89.8,
86.4, 60.8 (Ca). HR ESI-MS (CH3CN) m/z = 340.1190 [M + H]
+
(calc. for C20H14N5O, 340.1204). IR: ν (cm
−1) 3326, 3294, 3163,
3020, 2148, 1644, 1585, 1424, 1329, 1246, 1156. Anal. calcd for
C20H15N5O: C, 70.37; H, 4.43; N, 20.52%. Found: C, 70.21;
H, 4.54; N, 20.52%.
Synthesis of [Pd2(tripy)4](BF4)4. A solution of tripy (62 mg,
0.20 mmol) and [Pd(CH3CN)4](BF4)2 (44 mg, 0.10 mmol) in
acetonitrile (6 mL) was stirred for 1 hour. Vapor diﬀusion with
diethyl ether gave a white solid (76 mg, 0.040 mmol, 85%).
1H NMR (500 MHz, CD3CN, 298 K) δ: 9.32 (8H, d, J = 1.8 Hz,
Hc), 9.05 (8H, dd, J = 6.1 Hz, 1.1 Hz, Hf), 8.17 (8H, dt, J =
8.0 Hz, 1.4 Hz, Hd), 7.65 (8H, ddd, J = 8.0 Hz, 5.9 Hz, 0.6 Hz,
He), 7.64 (8H, t, J = 0.8 Hz, Hb), 4.63 (8H, dd, J = 5.6 Hz, 0.8 Hz,
Ha), 3.57 (4H, t, J = 5.6 Hz, HOH).
13C NMR (125 MHz, CD3CN,
298 K) δ: 154.5, 154.4 (Cc), 151.4 (Cf ), 144.5 (Cd), 143.2, 128.5
(Ce), 126.5 (Cb), 124.1, 94.8, 83.2, 62.2 (Ca). HR ESI-MS
(CH3CN) m/z = 816.1313 [M − (BF4)2]2+ (calc. for
C80H52N12O4Pd2, 816.1313). IR: ν (cm
−1) 3211, 3097, 2976,
2921, 2852, 2220, 1685, 1595, 1545, 1483, 1420, 1043, 1027.
Anal. calcd for C80H52B4F16N12O4Pd2·3H2O: C, 51.67; H, 3.14;
N, 9.04%. Found: C, 51.87; H, 3.09; N, 8.71%.
Synthesis of [Pd2(2A-tripy)4](BF4)4. A solution of 2A-tripy
(40 mg, 0.12 mmol) and [Pd(CH3CN)4](BF4)4 (26 mg,
0.060 mmol) in 1.5 mL d6-DMSO in a tube was purged with N2
and was heated at 50 °C for 6 hours. Diethyl ether (30 mL) was
added and the solution shaken vigorously. After decanting the
liquid portion, the precipitate was suspended in CH2Cl2
(5 mL) and isolated by filtration. After washing with CH2Cl2
(5 mL), the solid was dried under vacuum at 60 °C for 4 days
to give the product as a red solid (32 mg, 0.017 mmol, 57%).
1H NMR (500 MHz, d6-DMSO, 298 K) δ: 8.77 (8H, d, J = 1.6 Hz,
Hc), 8.11 (8H, s, HNH), 7.84 (8H, dd, J = 8.9 Hz, 1.5 Hz, Hd),
7.56 (8H, s, Hb), 6.73 (8H, d, J = 8.9 Hz, He), 4.53 (8H, s, Ha).
13C NMR (500 MHz, d6-DMSO, 298 K) δ: 159.8, 153.5, 149.4
(Cc), 142.7 (Cd), 142.1, 125.3 (Cb), 112.6 (Ce), 107.7, 90.5, 84.6,
60.6 (Ca). ESI-MS (DMSO/CH3CN) m/z = 394.60 [M − 4(BF4)]4+
(calc. for C80H60N20O4Pd2, 394.58), 394.10 [Pd(2A-tripy)2]
2+
(calc. for C40H30N10O2Pd, 394.08). IR: ν (cm
−1) 337, 3194,
2210, 1637, 1546, 1513, 1411, 1025. Anal. calcd for
C80H60B4F16N20O4Pd2·5H2O·4DMSO: C, 45.50; H, 4.07;
N, 12.03%. Found: C, 45.24; H, 3.78; N, 12.29%.
Synthesis of [Pd2(3A-tripy)4](BF4)4. A solution of 3A-tripy
(60 mg, 0.18 mmol) and [Pd(CH3CN)4](BF4)4 (39 mg,
0.090 mmol) in d6-DMSO (0.75 mL) was sonicated for five
minutes. Addition of ethyl acetate (20 mL)) resulted in precipi-
tation of the product. The precipitate was collected by fil-
tration, and washed with ethyl acetate (15 mL) and diethyl
ether (15 mL) to give a brown solid (64 mg, 0.03 mmol, 75%).
OR A solution of 3A-tripy (60 mg, 0.18 mmol) and
[Pd(CH3CN)4](BF4)4 (39 mg, 0.090 mmol) in DMF (2 mL) was
sonicated for five minutes. Addition of ethyl acetate (20 mL)
resulted in precipitation of the product. The precipitate was
collected by filtration, and washed with ethyl acetate (15 mL)
and diethyl ether (15 mL) to give a brown solid (60 mg,
0.03 mmol, 70%). 1H NMR (500 MHz, d6-DMSO, 298 K) δ: 8.36
(8H, s, He), 8.26 (8H, s, Hc), 7.63 (8H, s, Hb), 7.30 (2H, s, Hd),
6.41 (8H, s, HNH), 5.59 (4H, br, HOH), 4.55 (8H, s, Ha).
13C NMR (125 MHz, d6-DMSO, 298 K) δ: 154.0, 146.9, 141.4,
138.3 (Cc), 135.9 (Ce), 125.3 (Cd), 125.1 (Cb), 120.7, 119.1, 91.9,
83.3, 60.7 (Ca). HR ESI-MS (DMSO/CH3CN) m/z = 394.5820
[M − 4(BF4)4]4+ (calc. for C80H60N20O4, 394.5797), 342.1401
[3A-tripy + H]+ (calc. for C20H16N5O, 342.1401). IR: ν (cm
−1)
3468, 3384, 3230, 2220, 1637, 1592, 1547, 1443, 1020. Anal.
calcd for C80H60B4F16N20O4Pd2·5H2O·4DMSO: C, 45.50;
H, 4.07; N, 12.03%. Found: C, 45.20; H, 3.77; N, 12.28%.
X-ray crystallography [Pd2(2A-tripy)4](BF4)4
Yellow block crystals of [Pd2(2A-tripy)4](BF4)4 were grown by
vapour diﬀusion of diethyl ether in a solution of MeCN. X-ray
data were collected at 100(1) K on an Agilent Technologies
Supernova system using Cu Kα radiation with exposures over
1.0°, and data were treated using CrysAlisPro28 software. The
structure was solved using Sir-97 29 and weighted full-matrix
refinement on F2 was carried out using SHELXL-97 30 running
within the WinGX package.31 All non-hydrogen atoms were
refined anisotropically. Hydrogen atoms were placed in calcu-
lated positions and refined using a riding model. The structure
was solved in the primitive tetragonal space group P4/m and
refined to an R1 value of 14.4%. The asymmetric unit contains
two half ligands and two quarter occupancy palladium
ions. The counter-anions and solvent molecules present in the
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solvent lattice were severely disordered and could not be
appropriately modelled. The SQUEEZE routine within PLATON
was employed to resolve this problem, resulting in ten void
spaces (total of 460 electrons), variously assigned to tetra-
fluoroborate anions (8 in total), H2O (5 in total) and MeCN
(3 in total) solvent molecules (total of 444 electrons), as
described below. Despite repeated eﬀorts (>50 crystallisations
and data collections over a two year period) to crystallise the
compound, the most suitable candidate was small and a poor
diﬀractor. The data quality is poor, with two A alerts
(a large Hirshfield diﬀerence and high MainMol Ueq. com-
pared to neighbours) and many B alerts, and we emphasise
that metric data cannot be reliably extracted from the structure
and should be treated with caution. However, the connectivity
of the cationic framework is readily apparent. The methylene
alcohol substituents from the four neighbouring cages in the
lattice interpenetrate the cavity of each cage (Fig. 3 and ESI†),
interpenetrating groups shown in spacefilling mode (yellow,
green, blue and pink) and preclude cisplatin encapsulation in
the solid state. Around the coordinating pyridine rings, the
amino groups form a hydrogen bonding network. SQUEEZE
details and crystallographic parameters can be found in the
ESI.†
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